NEYT, CECILE ANNE,POOLMAN, JAN,LECRENIER, NICOLAS PIERRE FERNAND,CASTADO, CINDY
申请号：
NZ59369305
公开号：
NZ593693A
申请日:
2005.09.20
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
593693 Disclosed is the use of an immunogenic composition comprising: a) at least one isolated staphylococcal extracellular component binding protein or immunogenic fragment thereof selected from the group consisting of SdrG, laminin receptor, EbhA, EbhB, Elastin binding protein (EbpS), EFB (FIB), SBI, autolysin, ClfA, SdrC, SdrH, Lipase GehD, SasA, FnbA, FnbB, Cna, ClfB, FbpA, Npase, IsaA/PisA, SsaA, EPB, SSP-1, SSP-2, HBP, Vitronectin binding protein, coagulase and MAP and c) at least one isolated staphylococcal toxin or immunogenic fragment thereof selected from the group consisting of alpha toxin (Hla) and alpha toxin H35R mutant wherein said immunogenic fragments are capable of eliciting a protective immune response against Staphylococcal infection in the manufacture of a vaccine for treatment or prevention of staphylococcal infection.
